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Objectives This study sought to assess the impact of coronary bifurcation stenting on health-related func-
tional status, using the Seattle Angina Questionnaire (SAQ), for participants in the BBC ONE (British Bifurcation
Coronary; Old, New, and Evolving Strategies) trial and to compare simple versus complex bifurcation stenting
strategies in this regard.
Background Large randomized studies have examined outcomes from bifurcation stenting with drug-
eluting stents. They have reported on major adverse cardiovascular events and angiographic follow-up. How-
ever, a principal goal of percutaneous coronary intervention is symptom control and improvement in quality
of life, yet there are no published data from these trials on this aspect. Furthermore, it is unknown whether
simple versus complex stenting strategies have different effects on angina control and quality of life.
Methods The BBC ONE study randomized 500 subjects to bifurcation stenting using either a simple (provi-
sional T) or complex (crush or culotte) approach. Subjects completed the SAQ at baseline and at 9 months
after percutaneous coronary intervention. Canadian Cardiovascular Society class and antianginal drug use were
also evaluated.
Results Bifurcation stenting was associated with signiﬁcant improvements on SAQ scales and in Canadian
Cardiovascular Society class (baseline: 5.3% subjects were class 0; follow-up: 64.0% were class 0; p  0.001)
and a signiﬁcant reduction in the number of antianginal drugs used (median decrease: 1; p  0.001). Simple
nd complex strategies did not differ signiﬁcantly for changes in the SAQ, actual SAQ scores, or use of anti-
nginal drugs.
onclusions Regardless of chosen strategy, bifurcation stenting produced signiﬁcant functional improve-
ents in angina-related health. No signiﬁcant difference between simple and complex strategies was found in
his regard. (J Am Coll Cardiol Intv 2013;6:139–45) © 2013 by the American College of Cardiology
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140Lesions at coronary bifurcations have been associated with
poorer outcomes from percutaneous coronary intervention
(PCI) when compared with those not involving a branch,
mostly due to problems affecting the side branch (1). The
optimal strategy for treating bifurcations in the drug-eluting
stent (DES) era has been examined in large randomized
controlled trials (2–5). The BBC ONE (British Bifurcation
Coronary; Old, New, and Evolving Strategies) trial ran-
domized 500 patients to treatment of bifurcation lesions by
either simple (planned main vessel only, T-stenting if
required) versus complex (planned crush or culotte) strate-
gies (3). The primary endpoint was a composite of death,
See page 146
myocardial infarction, or target vessel failure at 9-month
follow-up and occurred significantly more often in the
complex stenting group, driven principally by a greater
number of myocardial infarctions. Inclusion of routine
periprocedural enzyme measurements to diagnose myocar-
dial infarctions may explain why more myocardial infarc-
tions were seen with complex stenting than in the previously
published large Nordic Bifurca-
tion Study (2). A recent patient-
level combined analysis of the
Nordic and BBC ONE trials
found more adverse clinical
events with a complex stenting
strategy, again driven by an ex-
cess of myocardial infarction (6).
Other bifurcation studies com-
paring simple and complex ap-
proaches, such as the CACTUS
(Coronary Bifurcations: Appli-
cation of the Crushing Technique Using Sirolimus-Eluting
Stents) study and BBK (Bifurcations Bad Krozingen), did
not include routine periprocedural enzyme measurements
and did not find any major adverse cardiovascular event
differences (4,5).
A major aim of PCI is symptom control and improve-
ment in quality of life, yet the large published studies on
bifurcation strategy have tended to focus on major
adverse cardiovascular events and on angiographic out-
Abbreviations
and Acronyms
CCS  Canadian
Cardiovascular Society
DES  drug-eluting stent(s)
IQR  interquartile range
PCI  percutaneous
coronary intervention
SAQ  Seattle Angina
Questionnaire
Table 1. Nonparametric Testing Comparing Baseline and 9-Month Follow-U
Scale of SAQ
Pre-PCI
Median, IQR, Range
Angina frequency scale 70, 40–90, 0–100
Angina stability scale 50, 25–75, 0–100
Physical limitation scale 63.9, 44.4–83.3, 0–100
Treatment satisfaction scale 93.8, 81.3–100, 31.3–100
Disease perception scale 41.6, 25.0–58.3, 0–100BBC ONE British Bifurcation Coronary; Old, New, and Evolving Strategies; IQR interquartile range; PCIcomes. Angiographic appearances are of minimal impor-
tance to most patients. From a patient perspective, an
improvement in symptoms and, more generally, func-
tional status relating to their coronary artery disease is
usually the primary concern. There is a paucity of published
data on this aspect for the treatment of bifurcation lesions,
although such data could undoubtedly contribute to informed
decision making by operators dealing with such lesions. There-
fore, we present here a prospectively performed quality-of-life
analysis for simple versus complex bifurcation treatment, un-
dertaken as part of the multicenter BBC ONE study.
The Seattle Angina Questionnaire (SAQ) assesses a broader
spectrum of disease effects than other measures, such as the
Canadian Cardiovascular Society (CCS) score or the Duke
Activity Status Index, do (7). It also provides a more disease-
specific measure than, for example, the Duke Index, the
Specific Activity Scale, or the short form 36. SAQ has been
used in hundreds of published studies, including the recent
COURAGE (Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation) and SYNTAX (Syn-
ergy Between Percutaneous Coronary Intervention With
Taxus and Cardiac Surgery) trials (8,9). Therefore, it was
chosen here to examine functional outcomes from bifurca-
tion coronary stenting.
Methods
The methodology used in the BBC ONE study has been
published elsewhere (3). Five hundred patients were ran-
domized to either a simple or complex bifurcation stent
strategy. The simple strategy involved planned stenting of
main vessel only, with provisional treatment of the side
branch. The complex strategy involved planned main vessel
and side branch stenting from the outset, involving either
culotte or crush technique based on operator preference.
Baseline demographics of the study cohort are given in
Table 1 of the original BBC ONE paper (3). Subjects
entering the study received the standard 19-point SAQ,
shown in Appendix 1 of that paper. They also underwent
assessment of CCS score and documentation of the number
of antianginal medications being taken. Baseline question-
naires were completed by the subjects before PCI. The same
e Points for the Overall BBC ONE Study Cohort
9-Month Post-PCI Follow-Up
Median, IQR, Range
Wilcoxon Signed-Rank Test
for Pre-PCI vs. Post-PCI
100, 80–100, 10–100 p  0.001
100, 50–100, 0–100 p  0.001
88.9, 69.4–100, 0–100 p  0.001
100, 87.5–100, 18.8–100 p  0.22
83.3, 66.7–91.7, 0–100 p  0.001p Timpercutaneous coronary intervention; SAQ Seattle Angina Questionnaire.
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141questionnaire format was used again at the mandated
9-month post-PCI follow-up visit.
SAQ comprises 5 scales that measure different aspects of the
potential functional impact of coronary artery disease. These
scales are: 1) physical activity; 2) angina stability; 3) angina
frequency; 4) treatment satisfaction; 5) disease perception. The
score for each scale is transformed to a value in the 0 to 100
range, with lower values reflecting lower levels of function for
that particular scale. There is no summation score for all 5
scales because the scales measure different aspects of function
that cannot be readily merged for the purposes of statistical
analysis.
Statistical analysis. Data were analyzed using GraphPad
rism (version 4.01, GraphPad Software, Inc., La Jolla, Cali-
ornia) and Minitab (version 15, Minitab Inc., State College,
ennsylvania). Nonparametric testing was employed to accom-
odate the distributional properties of the data.
For the overall study population (simple and complex
roups combined), Wilcoxon signed-rank testing was used
o analyze the change (in individual subjects) of SAQ scores,
CS scores, and number of antianginal medications be-
ween baseline and follow-up time points.
For assessing simple versus complex groups, Mann-
hitney U testing was used for between-group comparisons at
baseline and at follow-up. Mann-Whitney U testing was also
used to compare the change in SAQ scores (for each scale)
between the 2 time points, for subjects in simple versus
Figure 1. Seattle Angina Questionnaire Scores for the Overall BBC-ONE Stu
Scores at baseline and at nine months post-PCI are shown. * Signiﬁcant differe
scores on 4 out of the 5 SAQ scales. PCI  percutaneous coronary intervention.complex groups. Chi-square testing was used to compare the
proportions of patients in the 2 groups who were angina-free at
follow-up.
Results
Baseline characteristics of the study cohort have been
published previously and show excellent matching between
the 2 study arms in terms of age, sex, coronary risk factors,
presentation (acute vs. elective), number of diseased coro-
nary territories, location of bifurcation lesion, and adverse
anatomical factors.
Overall study population. Figures 1A to 1E show the scores
n each of the 5 scales of SAQ for the overall BBC ONE
tudy cohort at baseline (pre-PCI) compared with at the
-month post-PCI follow-up. Maximum value on each
cale is 100 and minimum is 0. On each scale, higher values
epresent better functional status. Statistical analysis is
hown in Table 1. It is seen that scores for all scales other
han treatment satisfaction score show a highly significant
mprovement after bifurcation PCI.
CCS scores at baseline showed an approximately bell-
haped distribution with median of 2, interquartile range
IQR) of 1 to 3, and full range of 0 to 4. In contrast, CCS
cores at 9-month follow-up showed a left-skewed distri-
ution with median of 0, IQR of 0 to 1, and full range of 0
o 4. The median decrease in CCS score between the 2 time
hort
etween pre- and post-PCI scores. Bifurcation PCI signiﬁcantly improveddy Co
nce b
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142points was 2 (IQR 1 to 2), with Wilcoxon signed-rank
testing confirming significant evidence for improvement in
angina class at follow-up (p  0.001).
Figure 2. Baseline (Pre-PCI) Scores on SAQ for Simple and Complex Group
Interquartile range shown in boxed region, full range within whisker bars. The
SAQ scales. Abbreviation as in Figure 1.
Figure 3. 9-Month Post-PCI Scores on SAQ for Simple and Complex Groups
Interquartile range shown in boxed region, full range within whisker bars. The
SAQ scales. Abbreviation as in Figure 1.The number of antianginal agents at baseline was median 2,
IQR 1 to 3, and full range 0 to 5. At follow-up, this had fallen to
median 1, IQR 1 to 2, and full range 0 to 5. Wilcoxon signed-rank
CI scores did not differ signiﬁcantly between the 2 groups for any of the
PCI scores did not differ signiﬁcantly between the two groups for any of thes
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143testing demonstrated a significant reduction (median 1) in the
number of antianginal drugs being used at follow-up compared to
baseline (p  0.001).
Simple versus complex treatment groups. Figures 2A to 2E
illustrate box plots for the 2 study groups for each of the 5
scales of the SAQ at baseline. The 2 study arms were very
closely matched in terms of baseline functional status, as is
expected with large subject numbers and randomized treat-
ment allocation.
Figures 3A to 3E show data for the 5 SAQ scales at the
9-month follow-up. Statistical analysis of the group data for
simple and complex cohorts is given in Table 2.
The corresponding graphs for simple and for complex
approaches appear very similar to each other for every scale
on the SAQ. This is borne out statistically, with no
significant difference emerging between the groups for any
scale at either time point.
Analysis of change in individual patients’ scores on each
SAQ scale (between baseline and follow-up) allowed a more
powerful statistical assessment of any potential difference in
outcomes between simple and complex groups. Score
changes (i.e., a subject’s 9-month post-PCI score minus
their baseline score) did not differ significantly between
simple and complex groups, for any of the 5 scales
(angina frequency score: p  0.65; angina stability score:
p  0.75; physical limitation score: p  0.60; treatment
satisfaction score: p  0.84; disease perception scale: p 
0.93). Figure 4 gives an indication of the proportions of
patients in each group whose scores improved, remained
unchanged, or deteriorated between baseline and follow-
up, for each scale of the SAQ. The close similarity
between simple and complex groups in this regard is
apparent in this figure.
The proportions of patients who were free of angina at
follow-up (score of 100 on angina frequency score on SAQ)
was 65.1% in the simple treatment group and 59.7% in the
complex group, which was not significant on chi-squared
testing (p  0.23).
The number of antianginal drugs at baseline in the
simple group was median 2, IQR 1 to 3, and full range 0
to 5. Median, IQR, and full range were identical in the
complex group at baseline. A Mann-Whitney U test
confirmed no significant evidence for difference between
the 2 groups in terms of baseline antianginal use (p 
0.67). At 9-month follow-up, the average number of
antianginal drugs had dropped in the simple group to
median 1, IQR 1 to 2, and full range 0 to 4. For the
complex group at follow-up, median number of drugs was
1, IQR 1 to 2, and full range 0 to 5. Mann-Whitney U
analysis again demonstrated no significant evidence for a
difference between simple and complex groups in anti-
anginal use at follow-up (p  0.96).T A A P T D A
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144Discussion
Coronary bifurcation lesions are frequently encountered in
interventional practice, due to a predilection for atheroma
development at sites of turbulent flow, such as arterial
branch points (10). Outcomes have been worse for PCI to
lesions at these sites when compared with nonbifurcation
lesions. The arrival of DES offered the prospect of more
complex treatment to both distal limbs of bifurcations
without the prohibitive in-stent restenosis rate seen with
bare-metal stents in this context (11). Several large random-
ized studies comparing simple and complex stenting ap-
proaches have been performed in the DES era. There has
been a signal for increased major adverse cardiovascular
events with complex stenting in some of these studies, as
discussed. Additionally, and consistent across all these
studies, simple stent strategies have clear benefits in terms of
lower procedural duration, procedural (equipment) costs,
contrast usage, and fluoroscopy exposure.
The 2 main aims of PCI in general are: 1) symptom
control and/or functional improvement; and, in some set-
tings and 2) a reduction in the risk of future events. For
stable patients undergoing elective treatment, it is the first
of these for which PCI is of clear proven benefit; hence,
strategies should be based on evidence of impact on this.
Such data in the context of bifurcation lesions have been
lacking. The data shown here demonstrate that bifurcation
stenting (irrespective of simple or complex strategy) is
associated with a highly significant and sustained improve-
Figure 4. Direction of Change in Individual Patients’ Scores on SAQ
Patients’ scores at baseline (pre-PCI) and at 9 month follow-up were compared
remained unchanged over this period, for each of the SAQ scales. A close sim
Abbreviations as in Figure 1.ment in health-related functional status and quality of life.The lack of difference in functional status between simple
and complex groups contrasts with a difference in the
primary endpoint of the main BBC ONE study. The
primary endpoint difference was driven particularly by
periprocedural enzyme rises, documented on mandated
blood tests. These events are frequently associated with
minimal symptoms and are often of debatable clinical
relevance (12). This might be reflected in our SAQ findings.
These findings counter the intuitive suggestion that a
simple strategy leaving a “pinched” side branch ostium
creates a substrate for future symptoms related to ischemia
in the side branch territory. The findings here fit with data
provided by Koo et al. (13) and more recently by Ahn et al.
(14), who demonstrated that many of these apparently
pinched side branch ostia are not functionally significant on
fractional flow reserve assessment. This is also in keeping
with “real-world” clinical experience, wherein only a minor-
ity of patients treated with a simple approach requires
further intervention due to ongoing angina symptoms at
subsequent review.
Study limitations. The time course of follow-up was 9
months after PCI, and it is possible that a difference
between groups would have emerged if patients had been
tracked for a longer duration after the procedure. This may
be relevant for in-stent restenosis and/or late or very late
stent thrombosis. Indeed, restenosis and stent thrombosis
were numerically greater for complex stenting although
there was no statistically significant difference when
graphs indicate the proportions of patients who improved, deteriorated, and
between ﬁndings in the simple and complex groups was again evident.. The
ilaritycompared with a simple strategy. This study used Taxus
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145stents (Boston Scientific, Natick, Massachusetts), which
are known to have greater late lumen loss and in-stent
restenosis (and stent thrombosis rate) than do second-
generation everolimus-eluting stents (15). This might
have disadvantaged the complex (2-stent) approaches
where restenosis is likely to be a greater problem than for
simple procedures.
Conclusions
The findings presented here fill an important gap in our
knowledge regarding outcomes after bifurcation stenting in
the DES era. A clear improvement in health-related func-
tional status and quality of life is seen with bifurcation PCI,
regardless of the technique employed. The lack of difference
in symptomatic and functional outcomes between simple
and complex approaches strengthens the argument that a
default simple strategy is preferable in most cases, given its
other proven advantages (reduced procedural duration, ra-
diation dose, equipment costs, and so on).
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